Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer-Reference-Cited by-同舟云学术

Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer

Published:2023-08-16 Issue:16 Volume:66 Page:11094-11117
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Deng Xiangping¹,Deng Xiaofei¹,Ning Wentao¹,Xin Lilan¹,Li Qiuzi²,Hu Zhiye¹,Xie Baohua¹,Liang Kaiwei³,Min Chang¹^ORCID,Dong Chune¹,Huang Jian²,Zhou Hai-Bing¹⁴^ORCID

Affiliation:

1. Department of Hematology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China

2. College of Life Sciences, Wuhan University, Bayi Road, Wuhan 430072, China

3. Department of Pathophysiology, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China

4. Frontier Science Center for Immunology and Metabolism, State Key Laboratory of Virology, Provincial Key Laboratory of Developmentally Originated Disease, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (MOE) and Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan University, Wuhan 430071, China

Funder

National Key Research and Development Program of China

Fundamental Research Funds for the Central Universities

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00465

Reference43 articles.

1. Cancer statistics, 2022